Webinar

Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice

Sunday, November 16, 2025
17:00 (Europe/London)

Add to Calender

Agenda

Learning objectives

After attending this webinar, learners will be able to:

  • Describe novel therapeutic targets in GvHD and explain the mechanisms of action for new agents.
  • Recall the latest data for new agents in development for GvHD and describe the rationale for selecting such treatments based on treatment- and patient-related factors.
  • Explain how quality of life can be impacted in patients with GvHD and how this can be better managed in clinical practice.

Our speakers

Meet our panel of experts

About SES

Delivering streamlined independent medical education to enhance clinical practice. SES hubs allow time-stretched healthcare professionals to easily access curated scientific, medical, and clinical information that expedites their learning and empowers their treatment decisions. Informed by patients, curated by world leaders, and endorsed by expert societies, our hubs support healthcare professionals worldwide with up-to-date, accessible, and impactful educational content.

Visit SES

About the AML Hub

The AML Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in AML. Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management. The AML Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage with treatment teams and researchers around the world.

Visit the AML Hub

Registration form

Registration is free.